WO2014120922A1 - Porous silica gel as a carrier for liquid technologies - Google Patents
Porous silica gel as a carrier for liquid technologies Download PDFInfo
- Publication number
- WO2014120922A1 WO2014120922A1 PCT/US2014/013848 US2014013848W WO2014120922A1 WO 2014120922 A1 WO2014120922 A1 WO 2014120922A1 US 2014013848 W US2014013848 W US 2014013848W WO 2014120922 A1 WO2014120922 A1 WO 2014120922A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inorganic oxide
- composition according
- oxide particles
- active ingredient
- biologically active
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 59
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title description 49
- 239000000741 silica gel Substances 0.000 title description 6
- 229910002027 silica gel Inorganic materials 0.000 title description 6
- 238000005516 engineering process Methods 0.000 title description 2
- 229910052809 inorganic oxide Inorganic materials 0.000 claims abstract description 278
- 239000000203 mixture Substances 0.000 claims abstract description 245
- 239000011148 porous material Substances 0.000 claims abstract description 188
- 239000004480 active ingredient Substances 0.000 claims abstract description 147
- 239000000463 material Substances 0.000 claims abstract description 135
- 239000002245 particle Substances 0.000 claims description 259
- 239000011344 liquid material Substances 0.000 claims description 115
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 82
- 238000001179 sorption measurement Methods 0.000 claims description 61
- 229910052757 nitrogen Inorganic materials 0.000 claims description 41
- 150000002632 lipids Chemical class 0.000 claims description 33
- 239000002904 solvent Substances 0.000 claims description 33
- 238000002156 mixing Methods 0.000 claims description 32
- 238000002459 porosimetry Methods 0.000 claims description 31
- 230000000284 resting effect Effects 0.000 claims description 29
- 239000004094 surface-active agent Substances 0.000 claims description 24
- 239000004615 ingredient Substances 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 23
- 230000007423 decrease Effects 0.000 claims description 20
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 17
- 238000009826 distribution Methods 0.000 claims description 17
- 238000003795 desorption Methods 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 241000238366 Cephalopoda Species 0.000 claims 1
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 73
- 239000003921 oil Substances 0.000 description 75
- 235000019198 oils Nutrition 0.000 description 75
- 239000003814 drug Substances 0.000 description 48
- 229940079593 drug Drugs 0.000 description 46
- 238000004090 dissolution Methods 0.000 description 34
- -1 for example Chemical compound 0.000 description 32
- 239000003826 tablet Substances 0.000 description 31
- 239000011149 active material Substances 0.000 description 25
- 238000009472 formulation Methods 0.000 description 23
- 238000011068 loading method Methods 0.000 description 23
- 239000000499 gel Substances 0.000 description 20
- 239000000377 silicon dioxide Substances 0.000 description 18
- 239000006185 dispersion Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 239000000969 carrier Substances 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 239000012876 carrier material Substances 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000012738 dissolution medium Substances 0.000 description 9
- 230000035699 permeability Effects 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 238000003801 milling Methods 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 238000012377 drug delivery Methods 0.000 description 7
- 229910010272 inorganic material Inorganic materials 0.000 description 7
- 239000011147 inorganic material Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 239000002738 chelating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 229960001295 tocopherol Drugs 0.000 description 6
- 239000011732 tocopherol Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 5
- 239000012736 aqueous medium Substances 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229960005489 paracetamol Drugs 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 229930003799 tocopherol Natural products 0.000 description 5
- 235000010384 tocopherol Nutrition 0.000 description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000011368 organic material Substances 0.000 description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000008159 sesame oil Substances 0.000 description 4
- 235000011803 sesame oil Nutrition 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 229910052681 coesite Inorganic materials 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 229910052906 cristobalite Inorganic materials 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 150000004679 hydroxides Chemical class 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000004576 sand Substances 0.000 description 3
- 150000004760 silicates Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 3
- 229910052682 stishovite Inorganic materials 0.000 description 3
- 150000003568 thioethers Chemical class 0.000 description 3
- 229910052905 tridymite Inorganic materials 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 2
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004115 Sodium Silicate Substances 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000004964 aerogel Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052910 alkali metal silicate Inorganic materials 0.000 description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 2
- 229960000766 danazol Drugs 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 150000002190 fatty acyls Chemical group 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000005470 impregnation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 229960004130 itraconazole Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052752 metalloid Inorganic materials 0.000 description 2
- 150000002738 metalloids Chemical class 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910052911 sodium silicate Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000004381 surface treatment Methods 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- AZLWQVJVINEILY-UHFFFAOYSA-N 2-(2-dodecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCOCCOCCO AZLWQVJVINEILY-UHFFFAOYSA-N 0.000 description 1
- WITKSCOBOCOGSC-UHFFFAOYSA-N 2-dodecanoyloxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCC WITKSCOBOCOGSC-UHFFFAOYSA-N 0.000 description 1
- SGRCVQDBWHCTIS-UHFFFAOYSA-N 2-nonanoyloxypropyl nonanoate Chemical compound CCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCC SGRCVQDBWHCTIS-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 108091008102 DNA aptamers Proteins 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 229960000892 attapulgite Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229960003065 bosentan Drugs 0.000 description 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- PBKVEOSEPXMKDN-LZHUFOCISA-N chembl2311030 Chemical class CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)CC)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 PBKVEOSEPXMKDN-LZHUFOCISA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229950006523 cilexetil Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000004064 cosurfactant Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- VTDCYOLLYVAJSY-UHFFFAOYSA-N cyclohexyl propan-2-yl carbonate Chemical compound CC(C)OC(=O)OC1CCCCC1 VTDCYOLLYVAJSY-UHFFFAOYSA-N 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229960000807 dihydroergotamine mesylate Drugs 0.000 description 1
- ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- PWVXXGRKLHYWKM-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 PWVXXGRKLHYWKM-LJQANCHMSA-N 0.000 description 1
- 229960002472 eletriptan Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- QBIRIYASLUPKQB-CBHLJOAQSA-N epierenone Chemical compound C1([C@]2(C)[C@H]3O[C@H]3C3[C@@]4(C)CCC(=O)C=C4C[C@H](C13)C(=O)OC)CC[C@@]21CCC(=O)O1 QBIRIYASLUPKQB-CBHLJOAQSA-N 0.000 description 1
- 229960000573 eprosartan mesylate Drugs 0.000 description 1
- DJSLTDBPKHORNY-XMMWENQYSA-N eprosartan methanesulfonate Chemical compound CS(O)(=O)=O.C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 DJSLTDBPKHORNY-XMMWENQYSA-N 0.000 description 1
- 229940040520 ergoloid mesylates Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 229910052909 inorganic silicate Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- CYPPCCJJKNISFK-UHFFFAOYSA-J kaolinite Chemical compound [OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[O-][Si](=O)O[Si]([O-])=O CYPPCCJJKNISFK-UHFFFAOYSA-J 0.000 description 1
- 229910052622 kaolinite Inorganic materials 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940100491 laureth-2 Drugs 0.000 description 1
- 229940062711 laureth-9 Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000012243 magnesium silicates Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- JABGXPCRNXUENL-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1N=CNC2=NC=N[C]12 JABGXPCRNXUENL-UHFFFAOYSA-N 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 229960002817 metolazone Drugs 0.000 description 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000012764 mineral filler Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229960004085 mosapride Drugs 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 238000002429 nitrogen sorption measurement Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052625 palygorskite Inorganic materials 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229910052699 polonium Inorganic materials 0.000 description 1
- HZEBHPIOVYHPMT-UHFFFAOYSA-N polonium atom Chemical compound [Po] HZEBHPIOVYHPMT-UHFFFAOYSA-N 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 238000006068 polycondensation reaction Methods 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229940116422 propylene glycol dicaprate Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 239000010499 rapseed oil Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 229940045845 sodium myristate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- JUQGWKYSEXPRGL-UHFFFAOYSA-M sodium;tetradecanoate Chemical compound [Na+].CCCCCCCCCCCCCC([O-])=O JUQGWKYSEXPRGL-UHFFFAOYSA-M 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 229940093609 tricaprylin Drugs 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
- 229960004010 zaleplon Drugs 0.000 description 1
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
- B01J20/103—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate comprising silica
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28002—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
- B01J20/28004—Sorbent size or size distribution, e.g. particle size
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
- B01J20/28057—Surface area, e.g. B.E.T specific surface area
- B01J20/28059—Surface area, e.g. B.E.T specific surface area being less than 100 m2/g
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
- B01J20/28069—Pore volume, e.g. total pore volume, mesopore volume, micropore volume
- B01J20/28073—Pore volume, e.g. total pore volume, mesopore volume, micropore volume being in the range 0.5-1.0 ml/g
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B33/00—Silicon; Compounds thereof
- C01B33/113—Silicon oxides; Hydrates thereof
- C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
- C01B33/18—Preparation of finely divided silica neither in sol nor in gel form; After-treatment thereof
- C01B33/187—Preparation of finely divided silica neither in sol nor in gel form; After-treatment thereof by acidic treatment of silicates
- C01B33/193—Preparation of finely divided silica neither in sol nor in gel form; After-treatment thereof by acidic treatment of silicates of aqueous solutions of silicates
Definitions
- the present invention relates to compositions comprising inorganic oxide porous material containing a biologically active ingredient in liquid form, methods of making such compositions; and methods of using them.
- the oral route remains the preferred route of drug administration due to its convenience and good patient compliance.
- Major problems in oral drug formulations are the erratic and incomplete absorption throughout the gastrointestinal (GI) tract, resulting in low and variable bioavailabilit ' and Sack of dose proportionality. These problems mainly result from poor aqueous solubility of the active ingredient, it has been reported that an estimated 40% of existing pharmaceutical active ingredients and an even higher proportion of all newly developed drugs are poorly soiubie or insoluble in water. This poses a major challenge to drug development, as there is a high need for producing suitable formulations to improve the solubility and bioavailability of such drugs.
- Methods that have been developed include the reduction of particle size of the drug by micronisation or nanonisaiion as to increase surface area, thereby increasing dissolution rate of the active ingredient. Further methods include solubilization in surfactant systems, water- soluble molecular complexes with cyelodextrins, converting the drug in amorphous form by lyophilization or formation of solid dispersions in hydrophiiie carriers, microencapsulation, and the release from porous carrier materials.
- Hpid based drug delivery system LBDDS
- the active ingredient is already in solution so that the drug is present on molecular level, avoiding the dissolution step from the crystalline state.
- the drugs in liquid phase are typically fdled into soft gelatin capsulees.
- iiquisoiid formulations which are porous carrier materials wherein the drugs remain in liquid form.
- Liquisolid forms are obtained by conversion of drugs in liquid form into acceptably flowing non-adherent and compressible powder mixtures by blending with selected carriers and coating materials. These then are converted into solid dosage forms such as tablets, pellets, and capsulees.
- Iiquisoiid dosage forms of water insoluble drugs show improved dissolution properties and bioavailability. This technique was successfully applied for low dose water-insoluble drugs.
- loadability and release of the drugs front the carriers used is limited, formulation of insoluble drags at higber doses is one of the limitations of the Iiquisoiid technique.
- Another problem associated with iiquisoiid formulations is their decreased flowability when loaded with higher amounts of drugs in liquid form. This causes these materials difficult to process in pharmaceutical manufacturing. In order to have acceptable flowability and compactabihty, high levels of carrier and coating materials have to be added thereby increasing the weight and volume of the resulting dosage forms,
- SEDDS self-emulsifying drug delivery systems
- This type of emulsion-based drug formulations can be used in soft gelatin capsulees or as Iiquisoiid formulations.
- SEDDS are isotropic and thermodynamically stable mixtures of drug, oil lipid, surfactant/cosurfactant, thai, in contact with aqueous fluids, spontaneously form oil-in-water emulsions of droplets, ranging in droplet size approximately between 100-300 nrn.
- SMEDDS self-micro-emulsifying drug delivery systems
- SNEDDS seif-nanoemulsifying drug delivery system
- SEDDS, SNEDDS and SMEDDS have also been converted into solid-SEDDS, solid-SNEDDS or soHd-SMEDDS (S-SEDDS, S-5MEDDS or S-SMEDDS) using liquisoiid solidification procedures similar as described above.
- S-SEDDS, S-5MEDDS or S-SMEDDS solid-SEDDS
- S-SMEDDS solid-SNEDDS
- soHd-SMEDDS S-SEDDS, S-5MEDDS or S-SMEDDS
- the resulting solid formulations in turn can be worked into various solid or semisolid dosage forms (tablets, pellets, capsules, creams, transdermal systems, etc).
- the present invention relates to a composition
- a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a liquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 ml/100 g; and (b) pores having a pore volume, as measured by nitrogen porosirnetry, of about 0.5 cm 3 /g or greater; wherein the inorganic oxide particles remain free flowing at a weight ratio of liquid material to inorganic oxide particles of at least 1.5: 1, or 1.6: 1 , or 1.7: 1 , or 1.8: 1, or 1.9: 1, up to 2: 1.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising at least one pharmaceutical dosage formulating ingredient and a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a liquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 mi/100 g; and (b) pores having a pore volume, as measured by nitrogen porosimetry, of about 0.5 cnr ' g or greater; wherein said inorganic oxide particles remain free flowing at a ratio of liquid material to inorganic oxide particles of at least 1.5 : i , or 1.6: 1 , or 1.7: 1 , or 1.8: 1 , or 1.9: 1 , up to 2: 1.
- the present invention relates to a method of making composition
- a method of making composition comprising porous inorganic oxide material containing a biologically active ingredient in a liquid material wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 ml/ 100 g; and (b) pores having a pore volume, as measured by nitrogen porosimetry, of about 0.5 em 3 /g or greater; wherein said inorganic oxide particles remain free flowing at a weight ratio of liquid material to inorganic oxide particles of at least 1 ,5: 1 , or 3 ,6: 1, or 1.7: 1, or 1 .8: 1. or 1 .9: 1 , up to 2: 1.
- the present invention concerns a method of making a pharmaceutical and/or cosmetic composition
- a pharmaceutical and/or cosmetic composition comprising at least one pharmaceutical dosage formulating ingredient and a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a Hquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 ml/100 g; and (b) pores having a pore volume, as measured by nitrogen porosimetry, of about 0.5 cnv'/g or greater; wherein said inorganic oxide particles remain free flowing at a weight ratio of liquid material to inorganic oxide particles of at least 1.5: 1, or 1 ,6: 1 , or 1 .7: 1 , or 1 ,8: 1 , or 1 ,9: 1 , or at least 2: 1 .
- the present invention relates to a composition
- a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a liquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 m 1/100 g; (b) pores having a pore volume, as measured by nitrogen porcsmietry, of about 0.5 cm 3 /g or greater; and (c) a pore size distribution having a relative span of about 1.5 or less, or about 1.4 or less, or about 1 ,3 or less, or about 1.2 or less, or about 1.1 or less, or about 1 .0 or less,
- the present invention concerns a composition
- a composition comprising porous Inorganic oxide particles containing a biologically active ingredient in a Hquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 ml/100 g; (b) pores having a pore volume, as measured by nitrogen porosimetry, of about 0.5 cm ' Vg or greater; and (c) a median pore size of 5 nm to 30 tint, wherein said inorganic oxide particles remain free flowing at a ratio of Hquid material to inorganic oxide particles of at least 1 : 1, or 1.3, or 1 ,5: 1, or 1 ,6: 1 , or 1.7: 1, or 1.8: 1 , or 1.9: 1, or at least 2: 1.
- the present invention relates to a composition
- a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a liquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 ml/100 g; (b) pores having a pore volume, as measured by nitrogen porosimetry, of about 0,5 cm " g or greater; and (c) a median particle size of from 3 microns to 10 mm; wherein said inorganic oxide particles remain free flowing at a ratio of liquid material to inorganic oxide particles of at least 1 : 1 , or 1 ,3, or 1.5: 1 , or 1 ,6: 1 , or 1.7: 1 , or 1.8: 1. or 1.9: 1 , or at least 2: 1.
- the present invention concerns a composition
- a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a liquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 mi/100 g; and (b) pores having a pore volume, as measured by nitrogen porosimetry, of about 0.5 cnrVg or greater; wherein said composition, after mixing the inorganic oxide particles and liquid material, decreases in volume of at least about 15% after resting, or at least about 20%, or at least about 25%, or at least about 30%, or at least about 35%, or at least about 40% after resting.
- the present invention relates to a composition
- a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a liquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 mi/100 g; and (b) pores having an pore volume, as measured by nitrogen porosimetry, of about 0.5 cnrVg or greater; wherein said composition, after mixing the inorganic oxide particles and liquid material, increases in bulk density by at least about 35% after resting, or at least about 20%, or at least about 25%, or at least about 30%, or at least about 35%, or at least about 40% after resting.
- the present invention concerns a composition
- a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a liquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 ml/100 g; and (b) pores having an pore volume, as measured by nitrogen porosimetry, of about 0.5 cm ' Vg or greater; wherein, after mixing the inorganic oxide particles and liquid material and then resting for at least 2 hours, at least about 400 mg of said composition may be loaded into a zero size capsule.
- at least about 410 mg, or at least about 420 trig, or at least about 430 rug of said composition may be loaded into a zero s e capsule.
- the present invention relates to a composition
- a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a Hquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 ml/100 g; (b) pores having an pore volume, as measured by nitrogen porosimetry, of about 0.5 enr/g or greater; and (c) a ratio of liquid material to inorganic oxide particles of at least 1 : 1 ; wherein at least 65% of the liquid material is desorbed from the particles upon desorption.
- the inorganic oxide material comprises porous particles comprising pores having a mean pore diameter in the range of about 5 nm to about 30 nm.
- the porous inorganic oxide material containing a biologically active ingredient in a liquid material is in the form of particles, i.e. particles of porous inorganic oxide material containing a biologically active ingredient in liquid form.
- the average diameter of the particles of porous inorganic oxide material of the invention may be in the range of from about 3 ⁇ to about 5 mm.
- compositions of the invention may contain further liquid organic auxiliary materials such as oils, non-volatile solvents, and surfactants.
- the particles of porous inorganic oxide material containing a biologically active ingredient in a Hquid material of the invention form a powder that is free-flowing.
- the powder has a Carr index of equal or lower than 25, or the powder has a Hausner index of about 1 to about 1 ,4.
- the angle of repose of said powder is from about 30 i! to about 45 3 ⁇ 4 , These properties are measured before and after loading the biologically active ingredient on the porous inorganic oxide material.
- the composition comprising porous inorganic oxide material containing a biologically active ingredient in a liquid material has a bulk bulk density, after loading and resting during at least 2 hours, of at least 450 g/1.
- the resulting loaded porous Inorganic oxide material may show a limited (e.g. up to about 10%) or no increase, but in particular shows a decrease in volume when compared to the unloaded inorganic oxide porous material In one embodiment the decrease is up to about 30%, or up to about 20%, or up to about 10% (each % in this paragraph being volume/volume or v/v).
- a limited (e.g. up to about 10%) or no increase but in particular shows a decrease in volume when compared to the unloaded inorganic oxide porous material
- the decrease is up to about 30%, or up to about 20%, or up to about 10% (each % in this paragraph being volume/volume or v/v).
- Each of the changes in volume and/or density mentioned herein are after loadsng and resting up to 2 hours depending upon the liquid, and even up to 24 or 48 hours.
- a decrease of the volume or increase in density in particular the particular decreases of volume or increases in density mentioned herein, during a time period of about 3 hrs, in particular of about 2 hrs Is observed, after which time period no further decrease occurs and the volume stays substantially constant.
- compositions of the present invention advantageously do not .show the substantial increase of volume that is typically observed when loading art-known silicas with a biologically active ingredient in a liquid material This allows the manufacture of more compact dosage forms, which in turn contributes to better processabllity during pharmaceutical manufacturing and to better acceptability of the dosage forms by patients,
- the present invention concerns a pharmaceutical composition
- a pharmaceutical composition comprising at least one pharmaceutical dosage formulating ingredient and a composition comprising porous inorganic oxide material containing a biologically active ingredient in a liquid material, wherein the inorganic o ide material has the oil adsorption, the pore volume, and BET surface area, as specified herein, in one embodiment the said composition comprising inorganic oxide porous material containing a biologically active ingredient is in the form of particles.
- the present invention is further directed to methods of making the disclosed compositions, in one embodiment, the method of making a composition of the present invention comprises incorporating at least one biologically active ingredient in a liquid material into the porous inorganic oxide material having the oil adsorption, the pore volume, and BE T surface area, as specified herein.
- the present invention concerns a method of making a pharmaceutical composition
- a pharmaceutical composition comprising at least one pharmaceutical dosage formulating ingredient and a composition comprising porous inorganic oxide material containing a biologically active ingredient in a liquid material, wherein the inorganic oxide material has the oil adsorption, the pore volume, and BET surface area, as specified herein, said method comprising combining said pharmaceutical dosage formulating ingredient with said composition.
- the present invention is also directed to methods of using the disclosed compositions, in one embodiment, the method of using a composition of the present invention comprises administering a composition of the invention to a patient so as to deliver a biologically active material to the patient, wherein the composition comprises a porous inorganic oxide material containing a biologically active ingredient n a liquid material, wherein the inorganic oxide material has the oil adsorption, the pore volume, and BET surface area, as specified herein.
- the composition that is administered in particular is a pharmaceutical dosage form.
- the said inorganic oxide material is in the form of particles, in particular particles havin an average diameter as further specified herein.
- FIG. 1 graphically displays the kinetic behaviour or volume change over time of an esemplasy composition of the present invention
- FIG. 2 graphically displays capsule loading capacity change before and after resting of an exemplary composition of the present Invention according to Example 4.
- FIG. 3 graphically displays a release profile of acetaminophen from an exemplary composition of the present invention according to Example 6.
- FIG. 4 graphically displays a release profile of ascorbic acid from an exemplary composition of the present, invention according to Example 6.
- FIG, 5 graphically displays the release profile Gyburide from a solid SEDDS system of the present invention according to Example 8.
- biologically active ingredient means an active pharmaceutical ingredient (API), which provides a pharmacological activity or otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have direct effect In restoring, correcting or modifying physiological functions in humans. Even though this includes poorly soluble material, it may also include materials that range in solubility, including those listed in the BCS (Biopharmaceutic Classification System), which is a classification approach where drags (APIs) are divided into four classes based on the extent (high or low) of their aqueous solubility and permeability through the GI tract wail in particular intestinal.
- API active pharmaceutical ingredient
- these four classes are: (Group I) High Solubility and High Permeability drags, (Group ⁇ ) Low Solubility and High Permeability drugs, (Group ⁇ ) High Solubility and Low Permeability drugs and, (Group IV) Low solubility and Low Permeability drugs.
- bulk density means the mass of particulate matter, such as a powder, divided by the total volume occupied by the matter, and includes mtraparticle pore volume and interpariicle void volume,
- the term "free flowing” means the ability of a group of particles or a powder to move when a force (e.g., gravity, or other external force) is applied to it.
- a force e.g., gravity, or other external force
- Commonly used tests for measuring powder flow include the Hausner ratio, compressibility index (Carr index) or angle of repose.
- the compressibility index (Can index) and the Hausner ratio are determined by measurin both the bulk volume and the tapped volume of a powder.
- inorganic oxides is defined as binary oxygen compounds where the inorganic component is the cation and the oxide is the anion.
- the inorganic material includes metals may also include metalloids. Metals include those elements on the left of the diagonal line drawn from boron to polonium on the periodic table. Metalloids or semi-metals include those elements that are on the right of this line. Examples of inorganic oxides include silica, alumina, titania, zirconia, etc., and mixtures thereof.
- the term "intraparticle pore volume” means pore volume attributable to the spaces in the pore of the particles, as compared to interparticle pore volume, which is the pore volume attributable to the spaces between the particles (i.e., the interstitial space).
- lipid materia! or “lipid component” means organic materials comprising fatty acids and their derivatives, and substances related biosyntheticaiiy or functionally to these compounds. They include, but are not limited to, molecules that originate entirely or in part by carban ion-based condensations of thioesters (fatty acids, po!yketides, etc) and/or by carocation-based condensations of isoprene units (preno!s, sterols, etc.).
- ordered porous material' ' ' refers to porous particles that have an interna! structural order such that they possess a low angle X-ray diffraction patterns according to Bragg's Law.
- ordered mesoporous silica for example, MCM-41 , SBA- 15, TUD-1 , HMM-33 and FSM- 56,
- non-ordered porous material refers to porous particles possessing an internal structure such that they do not have a low angle X-ray diffraction pattern according to Bragg' s Law, Such materials may be formed via any known process including, but not limited to, a solution polymerization process such as for forming colloidal particles, a continuous flame hydrolysis technique such as for forming fused particles, a gel technique such as for forming gelled particles, and a precipitation technique such as for forming precipitated particles. The particles may be subsequently modified by autoclaving, flash drying, super critical fluid extracting, etching, or like processes.
- the particles may be composed of organic and/or inorganic materials and combinations thereof, in one exemplar ⁇ ' embodiment the particles are composed of inorganic materials such as inorganic oxides, sulfides, hydroxides, carbonates, silicates, phosphates, etc, hut are preferably inorganic oxides.
- the particles may be a variety of different symmetrical, asymmetrical or irregular shapes, including chain, rod or lath shape.
- the particles may have different structures including amorphous or crystalline, etc.
- the particles may include mixtures of particles comprising different compositions, sizes, shapes or physical structures, or that may be the same except for different surface treatments, Porosiiy of the particles may be intraparticle or interparticle in cases where smaller particles are agglomerated to form larger particles.
- the particles are composed of inorganic materials such as inorganic oxides, sulfides, hydroxides, carbonates, silicates, phosphates, etc, hut are preferably inorganic oxides.
- Porous materials include organic and inorganic materials, or hybrids thereof, and may be in the form of particles, monoliths, membranes, coatings, and the like.
- pore size distribution means the relative abundance of each pore size in a representative volume of porous inorganic particles.
- media pore size is the pore diameter below which 50% of the intraparticle pore volume resides.
- the term "relative span” is defined as meaning a measure of the breadth of pore size distribution.
- the “span” is measured by subtracting the d3 ⁇ 4o pore size (i.e., the pore size/diameter below which 10% of the pore volume resides) from the d3 ⁇ 43 ⁇ 4 pore size (i.e., the pore size/diameter below which 90% by pore volume resides) as measured by mercury porosimetry.
- the term “relative span” is defined as the ratio of (d3 ⁇ 4rdto)/dso. he span and relative span are determined using nitrogen sorption (BJH method) of the cumulative pore volume.
- the term "rested ' ' or “after resting” is used to indicate a period of time wherein the porous inorganic oxide materia! is allowed to stand undisturbed after loading with a biologically active ingredient in a liquid material.
- w/w means weight/weight and w/v means weight/volume.
- the present invention is directed to compositions comprising a biologically active material or ingredient and an inorganic oxide material, wherein the inorganic oxide material comprises porous particles. Efficient loading of biologically active materials in liquids or a liquid material onto vehicles for drug delivery is a concern for many biologically active materials and this invention relates to various embodiments that provide solutions to this problem, Applicants of the present invention have found that certain porous inorganic oxide materials having a specific sets of physical properties provide exceptional liquid loading and release of biologically active materials that are in various liquids or a liquid material
- the present invention reiates to a composition
- a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a liquid material, wherein the inorganic oxide particies possess (a) an oil adsorption of about 100 to about 500 mi/100 g; and (h) pores having a pore volume, as measured by nitrogen porosimetry, of about 0,5 cm3 ⁇ 4 or greater; wherein the inorganic oxide particles remain free flowing at a weight ratio of liquid material to inorganic oxide particles of at least 1 ,5: 1 , or 1 .6:1 , or 1 ,7: 1 , or 1.8: 1, or 1.9: 1 , up to 2: 1.
- the present invention relates to a method of making composition
- a method of making composition comprising porous inorganic oxide material containing a biologically active ingredient in a liquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 ml/100 g; and (b) pores having a pore volume * as measured by nitrogen porosimetry, of about 0,5 enrVg or greater; wherein said inorganic oxide particles remain free flowing at a weight ratio of liquid material to inorganic oxide particles of at least 1 .5: 1 , or 1.6: 1 , or 1.7: 1 , or 1 ,8: 1, or 1 ,9: 1, up to 2: 1.
- the present " invention concerns a method of making a pharmaceutical composition
- a pharmaceutical composition comprising at least one pharmaceutical dosage formulating ingredient and a composition comprising porous inorganic oxide particies containing a biologically active ingredient in a liquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 mi 100 g; and (b) pores having a pore volume, as measured by nitrogen porosimetry, of about 0,5 cm J g or greater; wherein said inorganic oxide particles remain free flowing at a weight ratio of liquid material to inorganic oxide particles of at least 1.5: 1 , or 1.6: 1, or 1.7: 1, or 1.8: 3 , or 1.9: 1, or at least 2: 1.
- the present invention concerns a composition
- a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a liquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 300 to about 500 ml/1 GO g; (b) pores having a pore volume, as measured by nitrogen porosimetry, of about 0,5 cm 3 /g or greater; and (e) a median pore size of 5 nm to 30 nm, wherein said inorganic oxide particles remain free flowing at a ratio of liquid material to inorganic oxide particles of at least 3 : 1 , or 13, or 1 ,5: 1, or 1.6: 1 , or 1.7: 1 , or 1 .8: 1 , or 1 ,9: 1 , or at least 2: 1.
- the present invention relates to a composition
- a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a liquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 ml/ 100 g; (b) pores having a pore volume, as measured by nitrogen porosimetry, of about 0,5 cm Vg or greater; and (c) a median particle size of from 3 microns to 10 mm; wherein said inorganic oxide particles remain free flowing at a ratio of liquid material to inorganic oxide particles of at least 1 : 1 , or 1 ,3. or 1 .5: 1 , or 1.6: 1 , or 1 ,7: 1, or 1.8: 1 , or 1.9: L or at least 2: 1 .
- the present invention relates to a composition
- a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a liquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 mi/100 g; (b) pores having an pore volume, as measured by nitrogen porosimetry, of about 0.5 eirf/g or greater; and (c) a pore size distribution where at least 0.5 cm 3 /g of pore volume are from pores ranging from 10 nm to 30 nm, at least 0.5 enrVg, at least 0.6 cm J /g , at least 0.8 cnrVg* at least 1.0 cm Vg, at least 1 ,2 cmVg, at least 1.4 cm ' Vg, or at least 1.6 cm 7g of pore volume arc from pores ranging from 10 nm to 30 nm,
- the present invention relates to a composition
- a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a liquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 ml/100 g; (b) pores having a pore volume, as measured by nitrogen porosimetry, of about 0,5 cm 3 /g or greater ; and (c) a pore size distribution having a relative span of about 1.5 or less, or about 1 ,4 or less, or about 1.3 or less, or about 1.2 or less, or about 1.1 or less, or about 1.0 or less.
- the porous inorganic oxide material containing a biologically active ingredient in a liquid material may be in the form of particles, which may have a variety of different symmetrical, asymmetrical or irregular shapes, including chain, rod or lath shape.
- the particles may include mixtures of particles comprising different compositions, sizes, shapes or physical structures,
- the average diameter of the particles of the porous inorganic oxide material of the invention may be in the range of from about 3 pm to about 5 mm, preferably from about 50 ⁇ (or about 44 ⁇ ) to about 500 pm; or from about 70 pm (or about 74 pm) to about 200 ⁇ ; or from about 50 pm (or about 44 ⁇ ) to about 350 pm (or about 149 pm); or from about 50 pm (or about 44 pm) to about 150 pm (or about 149 ⁇ : or from about 100 ⁇ (or about 105 ⁇ ) to about 120 ⁇ (or about 125 ⁇ ), or from about 48 pm (or about 44 pm) to about 65 ⁇ (or about 63 pm), or from about 90 ⁇ to about 130 ⁇ .
- the average diameters disclosed herein preferably are determined by Malvern instrumentation. The desired particle sizes can be obtained by milling and subsequent mesh sieving,
- the porous inorganic oxide materials may be formed via any known process including a solution polymerization process such as for forming colloidal particles, a continuous flame hydrolysis technique such as for forming fused particles, a gel technique such as for forming gelled particles, and a precipitation technique such as for forming precipitated particles.
- the particles may be subsequently modified by autociaving, flash drying, super critical fluid extracting, etching, or like processes.
- the particles are composed of inorganic materials such as inorganic oxides, sulfides, hydroxides, carbonates, silicates, phosphates, etc, hut are preferably inorganic oxides.
- the particles may include mixtures of particles comprising different compositions, sizes, shapes or physical structures, or that may be the same except for different surface treatments,
- Porous materials include organic and inorganic materials, or hybrids thereof and may be in the form of particles, monoliths, membranes, coatings, and the like.
- porous inorganic oxide material that is suitable for use in the present invention includes precipitated inorganic oxide particles and inorganic oxide gel particles. These inorganic oxides are referred to herein as “parent inorganic oxides", “parent particles”, or “parent dispersions”.
- the porous inorganic oxide materials are non-ordered, and may further possess random intraparticle porosity. Such materials have been found, when combined with the biologically active ingredient and liquid material, to provide beneficial adsorption and desorpiion (and dissolution) characteristics. Even though any inorganic oxide composition may be suitable for use in this invention (e.g., Si0 2 , AI2O3, AIPO4, MgO, TiOz, ZrO? etc.), one embodiment of the present invention includes amorphous precipitated silica and siliea gel.
- the inorganic oxides may also include mixed inorganic oxides such as SiC A ⁇ Os, MgO.SiO2.AbO 3 and the like.
- Mixed inorganic oxides are prepared by conventional blending or coge!ling procedures, in embodiments comprising gels, the dispersions are derived from porous inorganic oxide geis such as gels comprising Si0 2 , A !;.(),, A I FO4, MgO, TiOj, and ZrQ 2 ,
- the gels can be hydrogeis, aerogels, or xerogels.
- the inorganic oxide gels include a non-ordered porous silica gel that includes interpartiele pore volume.
- a silica gel may be prepared by mixing an aqueous solution of an alkali metal silicate (e.g., sodium silicate) with a strong acid such as nitric or sulfuric acid, the mixing being done under suitable conditions of agitation to form a clear silica sol which sets into a hydrogel, i.e., macroge!, in less than about one-half hour. The resulting gel is then washed.
- an alkali metal silicate e.g., sodium silicate
- a strong acid such as nitric or sulfuric acid
- the concentration of inorganic oxide, i.e., SiC ., formed in the hydrogel is usually in the range of about 10 and about 50, or between about 20 and about 35, or between about 30 and about 35 weight percent, with the pH of that gel being from about 1 to about 9, or 1 to about 4.
- a wide range of mixing temperatures can be employed, this range being typically from about 20 to about 50 ⁇ C.
- the newly formed hydrogeis are washed simply by immersion in a continuously moving stream of water, which leaches out the undesirable salts, leaving about 99.5 weight percent or more pure inorganic oxide behind.
- the pH, temperature, and duration of the washing will influence the physical properties of the siliea, such as surface area (SA) and pore volume (PV).
- Silica gei washed at 65-90" C.
- inorganic oxide gels such as alumina and mixed inorganic oxide gels such as siiiea/alismma cogels are also well known in the art, such as by conventional blending, co-gelation, co-precipitation, and the like. Methods for preparing such geis have been described in US 4,226,743.
- alumina gels are prepared by mixing alkali rnetai aluminaies and aluminum sulfate
- Cogels are prepared by cogeliing two or more metal oxides so that the geis are composited together.
- silica alumina cogels can be prepared by gelling an alkali metal silicate with an acid or acid salt, and then adding alkali metal aluminate, aging the mixture and subsequently adding aluminum sulfate. The gel is then washed using conventional techniques.
- Another embodiment of this invention is derived from dispersions of certain precipitated inorganic oxides. Reinforced precipitated silica such as that described in US 4,157,920 can also be used to prepare the dispersion of this invention.
- reinforced precipitated silicas can be prepared by first acidulating an alkali inorganic silicate to create an initial precipitate. The resulting precipitate is then reinforced or "post conditioned" by additional silicate and acid. The precipitate resulting from the second addition of silicate and acid comprises 10 to 70% by weight of the precipitate initially prepared. It is believed that the reinforced structure of this precipitate is more rigid than conventional precipitates as a result of the second precipitation,
- a liquid phase of the selected inorganic oxide is prepared.
- the parent dispersion should be in a state that can be wet milled.
- the medium for the liquid phase can be aqueous or non-aqueous, e.g., organic.
- the liquid phase can he residual water in inorganic oxide gels which have been drained, but not yet dried, and to which additional water is added to reslurry the gel.
- dried inorganic oxides e.g., xerogels
- the parent dispersion is then milled.
- the milling is conducted "wet", i.e., in liquid media.
- the general milling conditions can vary depending on the feed material, residence time, impeller speeds, and milling media particle size. The techniques for selecting and modifying these conditions to obtain the desired dispersions are known to those skilled in the art.
- the milling equipment used to mill the parent inorganic oxide particles should be of the type capable of severely milling and reducing materials to particles having the desired size, e.g., through mechanical action.
- Such mills are commercially available, with fluid energy mills, hammer mills, and sand mills being particularly suitable for this purpose.
- Hammer mills impart the necessary mechanical action through high speed metai blades
- sand mills impart the action through rapidly churning media such as zirconia or sand beads.
- Impact mills can also be used.
- milling is not needed, such as for air-set inorganic oxide gels.
- Such gels are formed by air- spraying an intimate mixture of an alkali metal solution (e.g., sodium silicate) with a suitable acid (e.g.. sulfuric acid) at such a concentration so that mixture gels during flight, before being collected in a suitable medium, generally water.
- an alkali metal solution e.g., sodium silicate
- a suitable acid e.g. sulfuric acid
- any resulting dispersion or powder may also be further processed.
- further processing is desirable if there is a need to prepare a relatively stable dispersion without the aid of dispersing agents, or if there is a significant population of particles that are larger than desired. Further processing may also be needed to insure that essentially all of the distribution of particles is below a certain size.
- the dispersion or powder is processed to separate the smaller particles from the larger particles. This separation can be created by centrifuging the inorganic oxide particles into a supernatant phase, which comprises the smaller particles of the final product and a settled phase which comprises the larger particles. The supernatant phase is then removed from the settled phase, e.g., by decanting.
- the supernatant two, three or more times to further remove large particles remaining after the initial centrifuge. It is also contemplated that the larger particles of a milled dispersion can separate over time under normal gravity conditions, and the supernatant can be removed by decanting. Depending on the product particle size targets, the settled phase also can be regarded as particles of this invention.
- the dispersion of particles or powder also can be modified after milling to insure a stable dispersion. This can be accomplished through pH adjustment, e.g., adding alkaline material, or by the addition of conventional dispersants.
- the inorganic oxide material in the compositions of the present invention may comprise two or more different and distinct types of porous particles.
- each type of porous particles provides a specific desorption and/or dissolution rate profile for the biologically active material in a liquid material so as to form a composite desorption and/or dissolution rate profile for the biologically active material.
- the surface of the inorganic oxide material in particular the surface in the pores, has not been chemically modified.
- the pores in the inorganic oxide material are open so that the active ingredient in a liquid material can enter the pores and become adsorbed at the surface of the pores, or can leave the pores as to release the active ingredient.
- the porous inorganic oxide material of the present invention has an oil adsorption of about 100 to about 600 ml/100 g, or of about 100 to about 500 ml/100 g, or of about 100 to about 450 ml/100 g, or of about 100 to about 400 ml/100 g, or of about 150 to about 400 ml/100 g, or of about 200 to about 400 nil/100 g .
- the oil adsorption values can be measured with standard methodology, in particular by titrating a predetermined quantity of the inorganic oxide materia! with an oil under constant mixing of the oil inorganic oxide material, until the mass shows excess of oil, such as done in ASTM D28 ! ,
- the inorganic oxide material in the compositions of the present invention is porous.
- the pores have a mean pore diameter of greater than 5 nm, or from about 5 nm to about 30 nm; or from about 10 nm to about 30 nm.
- the mean pore diameter is about 20 to about 25 nm.
- the porous inorganic oxide material has a pore volume of about 0,5 cnrVg or greater, or about 0,6 cm ' Vg or greater, or about 0,7 em 3 /g or greater.
- the upper limit of the pore volume is about 3.0 cm ' Vg, or about 2.3 cm'Vg.
- the porous inorganic oxide material has a BET surface area., as measured by nitrogen adsorption, of about 10 ni ' 7g or greater, or about 100 m ' Vg or greater, or of about 200 nr ' - ' g or greater, or of about 300 m ' Vg or greater.
- the upper limit of the BET surface area is about 1000 m 2 /g, or about B00 Vg, or of about 600 m 2 /g.
- the BET surface area may range from about 10 to about 1000 m'Vg, or about 100 to about 800 rn 2 ig, or about 150 to about 600 m'Vg, or about 200 to about 500 nrVg, or about 250 to about 400 m'Vg.
- the porous inorganic oxide material has (i) a mean pore diameter of from about 5 nm to about 30 nm, (si) a pore volume of about 0.7 cm ' Vg or greater, and (iii) a surface area of about 20 to about 500 m 2 /g, or greater, in another embodiment, this porous inorganic oxide material is in the form of particles, which may have a diameter from about 50 ⁇ ? (or about 44 pm) to about 150 ⁇ (or about 149 pm). n a further embodiment this inorganic oxide porous material has an oil adsorption of about 100 to about 500 ml/100 g. Such materials are attractive due to their superior properties in terms of high loading, hulk density, flowability, desorption and dissolution ehareteristies.
- the measurements of pore volume are generated by
- the porous inorganic oxide materia? containing a biologically active ingredient in a liquid material may be obtained from porous inorganic oxide material that do not contain a biologically active ingredient in a liquid material, which biologically active ingredient in a liquid material subsequently is added so that it is adsorped by the porous inorganic oxide material .
- the biologically active ingredient in a liquid material may be added during one or more of the steps of the preparation of the porous inorganic, oxide material.
- the inorganic oxide can be dispersed in a liquid compound, which is subsequently used as a reaetant or solvent or medium, which forms the biologically active composition of the present invention.
- the particles of porous inorganic oxide material of the invention may be free- flowing.
- said particles may have a Carr index of equal or lower than about 25, e.g, a Carr index of about 10 to about 25, In some embodiments the Carr index may be equal or lower than about 15, e.g. a Carr index of about 10 to about 15.
- the particles of porous inorganic oxide material of the invention may have a Hausner index of about 1 to about 1.4, in particular of about 1 ,2 to about 1.4,
- the particles of porous inorganic oxide materia! of the invention may have an angle of repose of about 30* to about 45".
- the Carr and Hausner index values and angles of repose mentioned herein apply to any of the particles of the invention having a w/w ratio of the biologically active ingredient in a liquid material to inorganic oxide inorganic oxide, as specified herein, and in particular where said w/w ratio is between about 0.5 ; 1 to about 2 : 3.
- the Carr and Hausner index values and angles of repose mentioned herein apply to any of the particles of the invention that are unloaded with biologically active ingredient in a liquid material.
- a Carr index greater than 25 is considered to be an indication of poor flowability.
- the present invention concerns a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a iiquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 300 to about 500 rnI/ ⁇ g;.
- a decrease of the volume or increase in density in particular the particular decreases of volume or increases in density mentioned herein, during a time period of about 3 hrs, in particular of about 2 hrs is observed, after which time period no further decrease occurs and the volume stays substantially constant,
- the present invention relates to a composition
- a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a liquid material wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 ml/100 g; and (b) pores having an pore volume, as measured by nitrogen porosimetry, of about 0.5 cnvVg or greater; wherein said composition, after mixing the inorganic oxide particles and liquid material, increases in bulk bulk density by at least about 15% after resting, or at least about 20%, or at least about 25%, or at least about 30%, or at least about 35%. or at least about 40% after resting.
- each of the changes in volume and3 ⁇ 4r density mentioned herein are after loading and resting up to 2 hours depending upon the Iiquid, and even up to 24 or 48 hours.
- a decrease of the volume or increase in density in particular the particular decreases of volume or increases in density mentioned herein, during a time period of about 3 hrs, in particular of about 2 hrs is observed, after which time period no further decrease occurs and the volume stays substantially constant.
- the present invention concerns a composition
- a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a liquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 ⁇ about 500 rnl ⁇ g; and (b) pores having an pore volume, as measured by nitrogen porosimetry, of about 0,5 cm 3 /g or greater; wherein, after mixing the inorganic oxide particles and liquid material and then resting for at least 2 hours, at least about 400 mg of the composition may be loaded into a zero size capsule.
- at least about 410 mg, or at least about 420 mg, or at least about 430 mg of said composition may be loaded into a zero size capsule.
- the present Invention relates to a composition
- a composition comprising porous inorganic oxide particles containing a biologically active ingredient in a liquid material, wherein the inorganic oxide particles possess (a) an oil adsorption of about 100 to about 500 ml/i OO g; (b) pores having an pore volume, as measured by nitrogen porosimetry. of about 0.5 cm J g or greater; and (c) a ratio of liquid material to inorganic oxide particles of at least 1 : 1 ; wherein at least 65% of the liquid material is desorbed from the particles upon desorption.
- At least 70%, or at least 75%, or at least 80%, or at least 85% of the liquid material is desorbed from the particles upon desorption.
- the liquid material is desorbed under conditions that simulate desorption of liquid material in biological fluids. Such tests are performed by intense mixing in aqueous medium, as set forth in Example 7.
- liquid form or “liquid material” in relation to biologically active ingredients refers to such ingredients that in themselves are liquids or to biologicaliy active ingredients brought into liquid form by various techniques including, for example, desorption and/or dissolution or conversion into a self-emulsifying drug deliver)' system, Such materials may also include solid biologically active ingredients that are suspended, dispersed or incorporated with liquids.
- liquid form or “liquid material” refers to biologically active ingredients as such or brought into liquid form that are liquid at room tremperaiure or at physiological temperature, or are liquid at temperatures ranging from about 0 t! C to about 60°C, in partuclar about 10°C to about 5G a C, or about 20°C to about 5 : C, Such materials may be solid at certain conditions (e.g., temperature, concentration, etc.) and liquid under other conditions.
- the porous inorganic oxide material in accordance with this invention contains a biologically active ingredient in liquid form.
- the term “contain” means that the porous inorganic oxide material is loaded with a biologically active ingredient, the term “loaded” meaning thai the active ingredient is adsorbed at the surface of the inorganic oxide material including the surface within the pores of the inorganic oxide material. A major part of the active ingredient may be incorporated in the pores of the inorganic oxide material.
- Such inorganic oxide materials with adsorbed biologically active ingredient are referred as "loaded inorganic oxide materials".
- the terms “loaded” and “incorporated” in this context arc meant to he equivalent,
- the w/w ratio of the biologically active ingredient in a liquid material (which comprises the biologically active ingredient itself as well as any added materials in the iiquid) to inorganic oxide is in the range of about 0,5: 1 to about 5: 1 , or of about 0.5: 1 to about 3: 1, or of about 0.5: 1 to about 2: 1, or of about 1 : 1 to about 2: 1 ,
- the composition comprising porous inorganic oxide material containing a biologically active ingredient in a liquid material may have a bulk density- of at least 450 g/1.
- said bulk density is in the range of from 450 g 1 to 750 g/1, in particular in the range of from 500 g/1 to 700 g/1, or in the range of from 550 g/i to 650 g/1,
- the biologically active ingredient in a liquid material is a liquid lipid drug.
- examples include vitamin A, vitamin E (dl-a-Tocopherol), paracetamol ascorbic acid, sesame oil miglyol, or combinations thereof.
- the biologically active ingredient in a liquid material takes the form of a solution or dispersion of the biologically active ingredient in a nonvolatile solvent, e.g. having a boiling point of above about 150 C.
- a nonvolatile solvent e.g. having a boiling point of above about 150 C.
- examples include glycerin, propylene glycol, liquid polyethylene glycols such as polyethylene glycol 200 and 400, polysorbates such as polysorbate 80, or an oil, Oils that can be used include long-chain triglyceride and medium-chain triglyceride oils with different degrees of saturation; vegetable oils such as olive oil, sunflower oil castor oil, linseed oil and the like; modified or hydro!
- the active ingredient is preferably in the form of micro- or of nanoparticles.
- concentration of the biologically active ingredient in the solution or dispersion is in the range of from 1 % to 90 %, or from ... (w w).
- the biologically active ingredient in a liquid material is a self-emulsifying drag delivery system (SEDDS) comprising an oily/Hpid component, a surfactant cosolvent, and a biologically active ingredient
- SEDDS self-emulsifying drag delivery system
- the oily/iipid component is generally a fatty acid ester or a medium/long chain saturated, partially unsaturated or unsaturated hydrocarbon, in liquid, semisolid or solid form at room temperature (e.g., solid lipid nanopartic!es, oily suspensions, submicron lipid emulsions, lipid implants, lipid microtubules, lipid mierobubhies, or lipid microspheres, etc).
- Examples include mineral oil, vegetable oil, modified or hydrolyzed vegetable oils, silicone oil, lanolin, liposomes, refined animal oil, fatty acids, fatty alcohols, and mono-/ t ⁇ tri- glyeerides, including long-chain triglyceride and medium-chain triglyceride oils with different degrees of saturation and semisynthetic medium-chain triglyceride oils having surfactant properties.
- oils comprised of one or more medium chain fatty acids esters of propylene glycol such as propylene glycol rnonocaprate, propylene glycol dicaprate, propylene glycol dicaprylate/dicaprate, propylene glycol dipelargonate, and propylene glycol dilaurate, triacetin, fats and oils such as olive oil, sesame oil, soybean oil, corn oil, rape oil, castor oil, coconut oil, and eucalyptus oik .
- propylene glycol such as propylene glycol rnonocaprate, propylene glycol dicaprate, propylene glycol dicaprylate/dicaprate, propylene glycol dipelargonate, and propylene glycol dilaurate, triacetin, fats and oils such as olive oil, sesame oil, soybean oil, corn oil, rape oil, castor oil, coconut oil, and eucalyptus oik .
- capryiic/eapric acid triglyceride iglyol ' 812
- a triglyceride such as tricaprylin and trilaurin
- po!yglycerm fatty acid esters such as tetraglycerin polyricinoleate, hexaglycerin polyricinoieate, condensed poiyricinoleate, and tetraglycerin mixed fatty acid esters .
- medium chain fatty acid is meant to refer to fatty acyi chains of between 6 and 14 carbons in length, more preferably between S and 12 carbons in length;
- long chain fatty acid is meant to refer to fatty acyl chains greater than 14 carbons in length;
- short chain fatty acid is meant to refer to fatty acyl chains less than 6 carbons in length.
- the oil components may be used in the SEDDS formulations of the present invention in any effective concentration, including, for example, in a concentration range of 5% to 80% (w/v).
- Preferred surfactants comprise non-ionic surfactants with a relatively high hydrophiiie-lipophilic balance (HLB) value usually in concentration ranges between 30% and 60% (w/w).
- HLB hydrophiiie-lipophilic balance
- the hydrophilic surfactant (HLB (hydrophile-lipophiSe balance) of 9,0 or higher that can be used include polyoxyethylene lauryl ethers (Laureth 2 (BL-2), Laureth 4.2 (BL-4.2), and Laureth 9 (BL-9), polyoxyethylene (20) sorbitan monococonut oil fatty acid ester ("Polysorbate 20"), Polysorbate 40, Polysorbate 80, Labrasol, D-ot -tocopherol polyethylene glycol 1000 succinate (Vitamin E TPGS NF), lauroyl polyoxyethylene glycerin (Gelucire 44/34), polyoxyethylene hydrogenated castor oil 40 , polyoxyethylene hydrogenaied castor oil 60 (HCQ-6G), poiyoxyethylene sorbitan rnonolaurate, poiyoxyethylene sorbitan monopalmitate, and poiyoxyethylene sorbitan monooleate,
- HLB hydrophilic surfactant
- Any effective non-aqueous protic coscken or combinations thereof, may be used in the SEDDS for use in the invention.
- Acceptable non-aqueous proiic solvents include any pharmaceutically acceptable mono-, dk tri-, or poly-hydroxy linear aliphatic and aromatic solvent, or combinations thereof.
- non-aqueous protic solvents include ethanol, propanol, benzyl alcohol, propylene glycol, liquid polyethylene glycols such as polyethylene glycoi 200 and 400, and glycerol
- the protic solvents may be used in the formulations of the present invention i any effective concentration, including, for example, in a concentration range of about 5% to about 50% (w/v).
- a chelating agent and/or a soluble antioxidant may be included in the SEDDS for use in the invention.
- Chelating agents may be added to enhance the stability of a hydrophobic drag in the SEDDS composition.
- Suitable optional chelating agents include any pharmaceutically acceptable chelating agent, such as citric acid, nia!eie acid, succinic acid, tartaric acid, EGTA (ethylene giyeol-bis ( (3-aminoethyl ether) tetraaeetic acid, or egtazie acid) and EDTA (ethylene diamine tetraaeetic acid, or edetic acid).
- Such chelating agents are available in various forms, e. g. 4 as sodium or potassium salts or as the free acids.
- Such chelating agents may be used in the formulations of the present invention in any effective concentration, including, for example, in a concentration range of between 0,01% and 10% (w/v),
- an absorption ⁇ promoter such as sodium salicylate, sodium deoxycholate, sodium myristate, or sodium dodecyl sulfate.
- the SEDDS formulations may contain an auxiliary solvent such as ethanol, propylene glycol, polyethylene glycoi, diethylenetriaminepentaacetic acid, diethanolamine, triethanolamine, ethylenediamine, monoethanoiamine, or N,N-dimethy!acetarnide.
- an auxiliary solvent such as ethanol, propylene glycol, polyethylene glycoi, diethylenetriaminepentaacetic acid, diethanolamine, triethanolamine, ethylenediamine, monoethanoiamine, or N,N-dimethy!acetarnide.
- the SEDDS formulation may be prepared by dissolving the drug in a mix of oil, surfactant and cosever.
- the biologically active material used in the compositions of the present invention may comprise any known biologically active material.
- biologically active ingredient is meant to cover any pharmaceutical or other active ingredient for administration to humans or animals, in particular to warm-blooded animals.
- the biologically active material may be an active pharmaceutical ingredient (API), which comprises include naiiirai, semi-synthetic or synthetic moiecules.
- the biologically active material comprises two or more active pharmaceutical ingredients (APIs) in combination with one another.
- Other biologically active ingredients include ingredients that have an effect on the general well-being or have an effect on the outer appearance (cosmetic) such as the skin, hair, lips, and eyes.
- Such ingredients include any agents for use in cleansing, beautifying, promoting attractiveness, or altering the appearance, for example moisturizers, oils, anti-wrinkle agents, fragrances, and the like.
- ingredients for nutritious applications include food supplements such as, for example, dietary food supplements, vitamins, minerals, fiber, fatty acids, and amino acids. Examples of such ingredients are Vitamin C, omega-3 fatty acids, carotenes, and flavonoids.
- biologically active in relation to compositions for cosmetic or nutricious applications also includes activity relating to the improvement of the outer part of the body, in particular of the dermis, as well as the general well-being of an individual.
- the active ingredient has a molecular weight below about
- the active ingredient for use in the invention may be soluble or insoluble in water or aqueous media, in particular physiological aqueous media.
- any solvent solubility is defined as the amount of a solvent (g) required to dissolve 1 g of a compound, whereby the following solubility qualifications are defined: 10- 30 g ("soluble”); 30-100 g (“sparingly soluble”); 100-1000 g ("slightly soluble”); 1000-10000 g ("very slightly soluble” or “poorly soluble”) and more than 10000 g (practically insoluble).
- the active ingredient is soluble or insoluble in water or aqueous media, in particular physiological aqueous media.
- the pharmaceutically active ingredient belongs to the so-called BCS classes I through IV, Classes I and III are the soluble drugs.
- the Biopharmaceutical Classification System (BCS) classifies drug substances based on their aqueous solubility and intestinal permeability into four classes: Class i— High Permeability, High Solubility: Class II— High Permeability, Low Solubility: Class Ill-Low Permeability, High Solubility; Class IV-Low Permeability, Low Solubility.
- the active ingredient has a partition coefficient (expressed as log P) that is in the range from 4 to 9, in the range from 3 and 8. in a further embodiment, the active ingredient has a pK A that allows the molecule to be in neutral (non-ionic form) at about pH 5-8,
- Exemplary APIs include, aiorvastatin, amiodarone, eandesartan ⁇ cilexetil, : earvedilol, elopidogrel bisulfate, dipyridamole, eprosartan mesylate, epierenone, ezetirnibe, felodipine, furosemide, isradipine, iovastatin, metolazone, nicardipine, nisoldipine, olmesartan medoxornil, propafenone HC1, qinapril, ramipril, simvastatin, telmisartan, trandoiapril, valsartan and other cardio-vascular active drugs; acyclovir, adefovir, dipivoxil, amphotericin, Amprenavir, cefrxirne, ceftazidime, clarithromycin,
- irinotecan melphalan.
- mer- captopurine mitotane, paclitaxel, valrubicin, vincristine and other drugs used in oncology
- azathioprine tacrolimus, cyclosporin, psmecroHrnus, siroHnms and other smmonosupressive drugs
- clozapine, eniacapone fluphenazine, imipramine, nefazodone, olanzapine, paroxetine, pimozide, sertraline, triazolam, zaleplon, ziprasidone, risperidone, carbamazepine and other drugs for CNS indications
- danazol dutasteride, medroxyprogesterone, estradiol raloxifene, sildenafil, tadalafi!, testosterone, vardenafii and other drugs used for reproductive health
- the APIs include ezetimimbe, giucoroniude, tadalafii, fenofibrate, danazol, Itraconazole, carbamazepine, gnseofu!vin, nifedipin.
- the active ingredients further include sugars, polysaccharides, vitamins, amino acids, peptides, prostaglandins, nucleic acids, nucleotides, nucleosides, as well as derivatives thereof. Also included are peptides, proteins, protein fragments, antibodies, small antibody fragments, and the like. The latter include Fv" fragments, single-chain Fv (scFv) antibodies, antibody Fab fragments, antibody Fab' fragments, antibody fragments of heavy or light chain CDRs, or nanobodies. Also encompassed are small oligonucleic acid or peptide molecules such as aptamers, for example DNA aptamers, RNA aptaraers or peptide aptamers.
- aptamers for example DNA aptamers, RNA aptaraers or peptide aptamers.
- the biologically active ingredient in a liquid material when loaded in the inorganic oxide material shows an increased release compared to the active ingredient as such, or to formulations containing the active ingredient and ingredients that do not influence release.
- Increased release may for example be an increase of 10%, or of 20%, or of 30%, or of 50%, of the weight percentage of active ingredient released under physiological conditions (pH, temperature).
- the biologically active Ingredient in a liquid material when loaded in the inorganic oxide material shows immediate release from the compositions of the invention
- immediate release meaning, for example, a release of at least 60% of the drug under physiological conditions (pll, temperature), such as within 60 minutes or less, such as within 30 or less, or within 20 minutes or less, or within 15 minutes or lexs,
- the step of incorporating the biologically active material into the inorganic oxide materia! typically comprises a variety of loading methods, including the solvent method and the incipient wetness method, which methods have been described in the prior art, or mere mixing without use of any solvent or other mixing aid.
- the inorganic oxide material is loaded with an aciive ingredient by treatment with a solution of the active ingredient in a liquid material after which the solvent is removed.
- the active ingredient in a liquid material thereby becomes adsorbed to the surface of the inorganic oxide material, including the surface within the pores of the inorganic oxide material.
- Appropriate organic solvents for use in this method include dichloromethane, 1 ,4-dioxane, tetrahydrofuran, 2-propanoL diethyl ether, ethyl acetate, acetonitrile, dimethySformamide, N-methyl ⁇ pyrrolidinone, hexane.
- a solution containing about 50 nig of active ingredient per ml can be used for loading active ingredients in inorganic oxide material.
- incipient wetness method also referred to as capillary impregnation or dry impregnation the inorganic oxide material is wetted with the active ingredient in a liquid material or in a concentrated solution and is drawn into the pores by capillar ⁇ ' action.
- porous inorganic oxide materials of the invention are particularly suited for this methodology as they show strong capillary action.
- no or very little solvent needs to be used thereby avoiding the removal of the solvent after the loading step.
- This offers an additional advantage over known liquisolid formulations, which require additional ingredients needed to help adsorption, in particular solvents, involving methods of premixing the carrier or the drug in a liquid material (lipid or SEDDS) with a solvent to improve the adsorption.
- solvents in medicines and other products for human or animal use are critically scrutinized while many solvents are banned. Solvents also have environmental implications as they are considered an important source of pollution.
- the liquid material may be loaded onto the inorganic oxide material by spraying, or any other known method of liquid adsorption onto porous materials.
- the biologically active ingredient in a liquid material either with or without solvent may have a viscosity that is selected such that it can be adequately adsorbed by the inorganic oxide material s in particular in terms of speed of adsorption, sufficient loading, and the like, it may for example have a viscosity below about 250 mPa.s, or below about 100 mPa.s, or below about 10 mPa.s, or below about 5 mPa.s, or below about i mPa.s.
- the lower limit of the viscosity may be about 0.1 mPa.s, or about 0.5 mPa.s.
- the inorganic oxide materials of the invention are very efficient adsorbants of biologically active ingredient in liquid form. Contrary to known porous materials, where adsorption takes place in a very short time after being brought in contact with the liquid material, the inorganic oxide materials of the invention adsorp biologically active ingredient in liquid form during longer periods of time, in particular during several hours, for example up to about 2, 3, or 4 hours, k is believed that the decrease in volume after resting is related to capillar ⁇ ' farces that continue to draw free liquid between the particles up into the pores of the particles. This attributes to the high loading capacity of the inorganic oxide materials of the invention.
- compositions of the present invention may in one or more additional steps formulated into a final dosage form, which may vary depending upon the marsner in which it is administered to the patient, Preferred are solid or semisolid dosage forms for oral administration, in particular pills, tablets, and eapsulees. Such dosage forms may be suitable for providing immediate or fast in vivo release of said biologically active species, or may be suitable for controlled release. This may include one or more pharmaceutically acceptable excipients
- compositions containing a biologically active material and an inorganic oxide material in accordance with this invention may be introduced at any time during the process, including the step designed to load the biologically active material into the pores of the inorganic oxide material, or afterwards in a separate step,
- compositions may also contain optional excipients.
- excipients may comprise any of the ingredients customarily employed in the art such as diluents, binding agents, granulating agents, giidants (flow aids), lubricants: disintegrants, sweeteners, flavors, and pigments to make the tablets visually attractive.
- excipients include hydroxypropylmethyl cellulose, crospovidone, magnesium s earate, lactose, and talc.
- compositions of the present invention may further comprise one or more pharmaceutically acceptable fillers selected, for example, from hydrocoiioids (such as xantl an gum), binding agents, giidants, lubricants, surfactants and diluents.
- binding agents such as starch, gelatin, glucose, alginic acid, sodium and calcium alginates, water-soluble acrylic (co) polymers, polyvinylpyrrolidone, polyaminoacids, ethylene-vinyi acetate copolymers and the like; natural and synthetic mineral fillers or giidants such as silica, magnesium silicates such as tale, diatornaceous earth, aluminum silicate such as kaolinite, montmorillonitc or mica, magnesium aluminum silicate such as attapulgite and vermieulite, carbon such as charcoal, sulphur and highly dispersed silicic acid polymers; water-soluble diluents such as lactose, sorbitol and the like.
- binding agents such as starch, gelatin, glucose, alginic acid, sodium and calcium alginates, water-soluble acrylic (co) polymers, polyvinylpyrrolidone, polyaminoacids, ethylene-vinyi acetate copolymers and
- compositions of the present invention may also be formulated into forms suitable for topical application such as an ointment, a cream, a gel, a liniment or balm, etc...
- the present invention is further directed to methods of using any of the herein disclosed compositions.
- the compositions, in particular the pharmaceutical compositions, of the present invention may be used as medicaments, in particular may be used as medicaments via the oral route.
- the present invention a method of administering a composition to a patient so as to deliver at least one biologically active material to the patient wherein the composition comprises at least one pharmaceutical dosage formulating ingredient of a porous inorganic oxide material containing a biologically active ingredient in liquid form, wherein the inorganic oxide material has the oil adsorption, the intraparticie pore volume, and BET surface area, as specified herein.
- the compositions in this method are preferably administered by various means, including by oral, buccal, sublingual, periodontal, vaginal intrauterine, rectal, pulmonary, nasal, inhalation, intraocular, ophthalmic, auricular, and topical means,
- One of the reasons for improved release of the biologically active material from the compositions of the present invention is due to the improved desorption of the liquid material from the inorganic oxide material.
- the presence of pores within the inorganic oxide materials i.e., intraparticie porosity
- the pore size distribution of the present inorganic oxide material is narrow (i.e., a small relative span), which allows for a number of pores to readily adsorb and desorb the liquid material.
- compositions in accordance with the invention provide attractive drug delivery properties. They provide desirable desorption and/or dissolution rate profiles for a variety of biologically active materials (e.g., APIs), in some embodiments, the biologically active material exhibits a percent release desorption and/or dissolution rate of about 20 or greater within about 15 minutes of an initial time of contact with a dissolution medium. In some embodiments, the biologically active material exhibits a percent release dissolution rate of about 25 or greater (or about 30 or greater; or about 35 or greater) within about 15 minutes of an initial time of contact with a dissolution medium.
- biologically active materials e.g., APIs
- the biologically active material exhibits a percent release desorption and/or dissolution rate of about 20 or greater within about 15 minutes of an initial time of contact with a dissolution medium. In some embodiments, the biologically active material exhibits a percent release dissolution rate of about 25 or greater (or about 30 or greater; or about 35 or greater) within about 15 minutes of an initial time of contact with a dissolution medium
- the biologically active material exhibits a percent release dissolution rate of about 20 or greater about 30 minutes after an initial time of contact with a dissolution medium, in some embodiments, the biologically active material exhibits a percent release dissolution rate of about 30 or greater about 30 minutes after an initial time of contact with a dissolution medium.
- the biologically active material exhibits a percent release dissolution rate of about 10 or greater about 60 minutes after an initial time of contact with a dissolution medium. In some embodiments, the biologically active material exhibits a percent release dissolution rate of about I S or greater (or about 20 or greater) about 60 minutes after an initial time of contact with a dissolution medium,
- compositions of the present invention in many instances show immediate release of the active ingredient but may be turned into controlled release compositions for example by coating the compositions with a suitable polymer.
- a suitable polymer When mixing compositions with sleeted polymer coatings mixed release patterns can be obtained such as a combination of immediate and sustained release.
- the inorganic oxide material may comprise two or more different and distinct types of porous particles with each distinct type of porous particles providing a specific desorption and/or dissolution rate profile for a single biologically active material (or two or more different biologically active materials) so as to form a composite desorption and/or dissolution rate profile.
- a further aspect of this invention concerns particles of a inorganic oxide material, wherein the inorganic oxide material wherein the inorganic oxide material has the oil adsorption, the intraparticle pore volume, and BET surface area, as specified herein.
- compositions of the present invention not only show high loadabiiity of drugs in liquid form, they moreover show higher bulk density compared to existing Siquisolid systems. Further favorable properties include the excellent adsorptive capacity of the inorganic oxide material of the invention and the increased stability of the active ingredient. These advantages are in particular offered by the compositions of the invention in the form of particles. [0138]
- the compositions of the present invention can also be used in dermatology and cosmetic applications because of their good skin-comparability and lack of unpleasant skin feel
- the DI G, D50 and D90 values indicate the 10 th , 50 th and 90 th percentiles of the weight of the particle diameter distribution. These values were obtained from a Malvern f M rV!astersizer 2000 instrument available from Malvern Instruments Ltd. PV: pore volume; SA: surface area; APD: average pore diameter; BET SA: surface area; and Relative Span are determined using BJH nitrogen adsorption at a pressure of 0.995 using an ASAP 2420HV accelerated surface area and porosimeiry system available from Micromeretics Instrument Corporation.
- Example 3 The Cremophor and Labrafii loaded materials of Example 3 were loaded into zero size capsules manually using a casule filling tray, such as the Cap- -Quick available from Empty Caps Company. As can be seen from FIG, 2, there ts a significant difference between the filling amounts before and after resting of the material The amounts of material loaded into the capsules are set forth in Tables 8 and 9.
- the ascorbic acid loaded carrier (S i ) was subjected to dissolution studies as per USP 30 for Ascorbic acid Tablets for 45 min.
- Dissolution test conditions comprised of use of USP dissolution apparatus 2 (Paddle) operated at speed of 50 PM for 45 minutes.
- Dissolution medium was 900 ml of water at 37 ⁇ Q,5 C.
- 100 rng of the weighed amount of drug loaded carrier was used to dissolution studies.
- Aliquots (5 ml) were withdrawn at 10, 20, 30 minute time intervals, filtered and diluted with water. Absorbance of aliquots was determined spectromeiricaliy at X ax 266nm.
- the release profile is illustrated in FIG, 4.
- the drug release from the both carriers S i and S2 met the USP criteria (NLT 75% in 45 minutes).
- Oil release or desorption The carrier material used in the following trials was the material designated S I prepared in Example 1 , 2 grams of oil loaded carrier ( 1 : 1 , w/w) prepared pursuant to method of Example 2 was mixed with 6 ml water in a beaker, vorlexed during 1 hour, and centrifuged at 5000 RPM for 10 min in a Heraeus Muitifuge 1 S ⁇ R centrifuge available from Thermo Electron Corporation. The supernatant, i.e. oil + water, was transferred into a petry dish and dried in hot air oven up to constant weight.
- the results which are based upon the w/w % release obtained in the trials., are as follows. For sesame oil, 81 % of the oil is released from the carrier materia! or inorganic oxide, and tor Miglyol 812, 81.3% of the oil is released from the carrier material or inorganic oxide.
- Solid SEDDS System Loading and Release (or Desorption) The carrier materials used in the following trials was the materials designated as SI and S2 in Example 1.
- a liquid SEDDS system was made up containing 0,6g of Giyburide as the API component, I Sg of Capryol®90 as the oil/vehicle component. 54.4g of Trascutoi® HP as a co-surfactan and 30g of Tween® 20 as a surfactant.
- This liquid SEDDS system was loaded onto SI and S2 by accurately weighing the required quantities of carrier and liquid SEDDS in the ratio of 1 : 1.
- Carrier and Liquid SEDDS were pre-heated at 60 °C for S 5 min, prior to mixing. Liquid SEDDS was added slowly to the carrier under stirring with metallic spatula. The prepared mixture was kept aside for around 24 hr to get free flowing powder.
- Dissolution test conditions comprised of use of USP dissolution apparatus 2 (paddle) operated at a speed of 75RPM.
- Dissolution medium was 500ml of pH 9.5 Borate Buffer (0.05M) at 37 ⁇ 1°C.
- a weighed amount of ioaded carrier or APi(non- micronized Gyburide) with an weight equivalent basis of 5rng Gyb ride were used for the dissolution studies.
- Cremophor® EL was the liquid lipid that was loaded on to the silica.
- Silica 52 was loaded pursuant to method of Example ⁇ and was used as the oil loaded carrier component in tablet formulations. To deliver oil in tablet dosage form, tablets were made with two different processes: direct compression (DC) and wet granulation (WG).
- DC direct compression
- WG wet granulation
- Direct compression tablets were obtained by accurately weighed the quantities of excipients for blend preparation.
- Diluent (MCC ) and Oil loaded carriers were sieved through #40 mesh and mixed well for approximately 5 min. Binders and disiniegrant were sieved through #40 mesh and added to the blend, then mixed well for approximately 5 min.
- GHdant was passed through #40 mesh and added to the blend and mixed well for 5 min.
- Lubricant was sieved through # 60 mesh and added to the blend and mixed well for approximately 2min. This final blend was used for the compression of the tablets.
- Ghdant was passed through #40 mesh and added to the blend and mixed well for 5 min.
- Lubricant (what material) was sieved through # 60 mesh and added to dried granules and mixed well for approximately 2mirt. This final blend was used for the compression of the tablets.
- Tablet hardness for all formulations was measured with EH 01 tablet hardness tester (Eleetrolab, India). The hardness for tested formulations are listed in Table Y below.
- Example 9 Additional excipients were added pursuant to the method in Example 9 to obtain a direct compression blend with the following composition : 70% Tocopherol loaded silica S2(l : 1 loaded), 12.5%MCCPH102, 34% PVP30, 2% AcDiSoi, 1 % SYLOSD® 244FP, 0.5% Magnesium Stearate. Tablets were prepared using a Parle Elizabeth tools Pvt Ltd, Eliza press 200 mu!ti tooling single rotary tablet press operated at a Speed of 5 rprn, compression force of 20kN, ejection force ⁇ 70N, and with a 12mm round bioconeave, D-tao!ing punch.
- Tablet hardness for all formulations was measured with EH 01 tablet hardness tester (Eieetrolab. India) at tablet weight of 5GiK-5rng. Tablet hardenss results for these tablets was 40N. Friability was 0% and disintegration time was ⁇ l min.
- Oil Release (Tocopherol) from Tablets The carrier materials used in the following trials was the material designated S2 in Example L Tocopherol was the liquid lipid that was loaded on to the silica. Silica S2 was loaded with liquid lipid pursuant to method of Example 8 and was used as the oil loaded carrier component in tablet. Tablets were prepared pursuant to the method in example 10. Tochopherol concentration in the tablet was 1 OOmg. [0168] Tablets prepared were .subjected to dissolution studies pursuant to the method described in Example 8. An aliquot of 2 mL was withdrawn at predetermined time interval and filtered through 0.22 ⁇ membrane filter. The dissolution samples were analyzed by using HPLC (Waters UPLC Wavelength: 294 rtm Column: Rocket Format, 53x7mm, 3 ⁇ ) Mobile Phase: 85% ACN: 10% MeOH: 5% H20.)
- any number R falling within the range is specifically disclosed, in particular, the following numbers R within the range are specifically disclosed: R ;; R L + k(Ru -RL) > where k is a variable ranging from ! % to 100% with a 1% increment e.g., k is 1 %, 2%, 3%, 4%, 5%. ... 50%, 51 , 52%. , , , 95%, 96%, 97%, 98%, 99%, or 100%.
- any numerical range represented by any two values of , as calculated above is also specifically disclosed.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Silicon Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL14746507T PL2950923T3 (en) | 2013-02-01 | 2014-01-30 | Porous silica gel as a carrier for liquid technologies |
CN201480019478.7A CN105102117A (en) | 2013-02-01 | 2014-01-30 | Porous silica gel as a carrier for liquid technologies |
JP2015556128A JP6513031B2 (en) | 2013-02-01 | 2014-01-30 | Porous silica gel as a carrier for liquid technology |
ES14746507T ES2908958T3 (en) | 2013-02-01 | 2014-01-30 | Porous silica gel as a carrier for liquid technologies |
US14/764,363 US10660856B2 (en) | 2013-02-01 | 2014-01-30 | Porous silica gel as a carrier for liquid technologies |
KR1020157023665A KR102229036B1 (en) | 2013-02-01 | 2014-01-30 | Porous silica gel as a carrier for liquid technologies |
EP14746507.4A EP2950923B1 (en) | 2013-02-01 | 2014-01-30 | Porous silica gel as a carrier for liquid technologies |
HK16105942.0A HK1217927A1 (en) | 2013-02-01 | 2016-05-25 | Porous silica gel as a carrier for liquid technologies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361759723P | 2013-02-01 | 2013-02-01 | |
US61/759,723 | 2013-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014120922A1 true WO2014120922A1 (en) | 2014-08-07 |
Family
ID=51262940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/013848 WO2014120922A1 (en) | 2013-02-01 | 2014-01-30 | Porous silica gel as a carrier for liquid technologies |
Country Status (9)
Country | Link |
---|---|
US (1) | US10660856B2 (en) |
EP (1) | EP2950923B1 (en) |
JP (2) | JP6513031B2 (en) |
KR (1) | KR102229036B1 (en) |
CN (2) | CN105102117A (en) |
ES (1) | ES2908958T3 (en) |
HK (1) | HK1217927A1 (en) |
PL (1) | PL2950923T3 (en) |
WO (1) | WO2014120922A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10786459B2 (en) * | 2016-04-22 | 2020-09-29 | R. P. Scherer Technologies Llc | Twin-screw dry granulation for producing solid formulations |
WO2019045501A1 (en) * | 2017-09-01 | 2019-03-07 | 제이더블유중외제약 주식회사 | Solid preparation comprising dutasteride and method for preparing same |
WO2020071539A1 (en) * | 2018-10-05 | 2020-04-09 | 富士化学工業株式会社 | Porous silica particle composition |
CN111751480B (en) * | 2020-07-16 | 2021-06-15 | 北京理工大学 | Application of vitamin E polyethylene glycol succinate |
CN116159031B (en) * | 2023-02-22 | 2023-08-22 | 上海国创医药股份有限公司 | Fluvoxamine maleate tablet and preparation method thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4157920A (en) | 1975-03-12 | 1979-06-12 | J. M. Huber Corporation | Novel precipitated siliceous products and methods for their use and production |
US4226743A (en) | 1979-03-12 | 1980-10-07 | W. R. Grace & Co. | Silica-alumina hydrogel catalyst |
US20030152771A1 (en) * | 1999-04-22 | 2003-08-14 | Preston Barry W. | Very high structure, highly absorptive hybrid silica and methods for making same |
WO2004073689A1 (en) | 2003-02-19 | 2004-09-02 | Lifecycle Pharma A/S | Use of a silica or silica derivative as a sorption material |
US20050112232A1 (en) * | 2002-04-30 | 2005-05-26 | Jean-Marie Dollat | Animal feed supplement |
US20090311159A1 (en) * | 2006-08-22 | 2009-12-17 | Evonik Degussa Gmbh | Fumed silica for use as auxiliary in pharmaceutical and cosmetic compositions |
WO2011144346A1 (en) * | 2010-05-21 | 2011-11-24 | Grace Gmbh & Co. Kg | Porous inorganic oxide particles and methods of making and using the same |
US20120269792A1 (en) * | 2001-11-14 | 2012-10-25 | Jarrow Formulas, Inc. | Eutectic-based self-nanoemulsified drug delivery system |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4629588A (en) * | 1984-12-07 | 1986-12-16 | W. R. Grace & Co. | Method for refining glyceride oils using amorphous silica |
US5256386A (en) * | 1987-06-29 | 1993-10-26 | Eka Nobel Ab | Method for preparation of silica particles |
PL176934B1 (en) * | 1991-03-16 | 1999-08-31 | Torf Ets | Bioactive products obtained from as well as pharmaceutical and cosmetic compositions containing such products |
DE4429644A1 (en) * | 1994-08-20 | 1996-02-22 | Sued Chemie Ag | iodine adsorbent |
US5800834A (en) | 1996-06-10 | 1998-09-01 | Spireas; Spiridon | Liquisolid systems and methods of preparing same |
US6096337A (en) | 1996-06-10 | 2000-08-01 | Spireas; Spiridon | Liquisolid systems and methods of preparing same |
JPH10130013A (en) * | 1996-09-09 | 1998-05-19 | Toyota Central Res & Dev Lab Inc | Cluster inclusion material |
FR2767071B1 (en) * | 1997-08-06 | 1999-09-10 | Rhodia Chimie Sa | COMPOSITION COMPRISING A LIQUID ABSORBED ON A PRECIPITATED SILICA BASE |
JPH11157827A (en) * | 1997-11-21 | 1999-06-15 | Shionogi & Co Ltd | New silicon dioxide |
SE9704400D0 (en) | 1997-11-28 | 1997-11-28 | Astra Ab | Porous inorganic particles as carriers for drug substances |
US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US6790814B1 (en) | 1999-12-03 | 2004-09-14 | Procter & Gamble Company | Delivery system having encapsulated porous carrier loaded with additives, particularly detergent additives such as perfumes |
GB2365769A (en) | 2000-08-18 | 2002-02-27 | Secr Defence | Skin preparations containing silicon |
DE10153078A1 (en) * | 2001-10-30 | 2003-05-22 | Degussa | Use of granules based on pyrogenic silicon dioxide in pharmaceutical compositions |
DE10244397A1 (en) | 2002-09-24 | 2004-04-01 | Basf Ag | Choline formulations |
FR2850576B1 (en) | 2003-02-05 | 2007-03-23 | Ethypharm Sa | COMPOSITION COMPRISING A MIXTURE OF ACTIVE INGREDIENTS AND PROCESS FOR PREPARING THE SAME |
FR2851918B1 (en) * | 2003-03-06 | 2006-06-16 | IMPREGNATED POWDER ENHANCING BIOAVAILABILITY AND / OR SOLUBILITY AND METHOD OF MANUFACTURE | |
ES2293241T3 (en) | 2003-03-27 | 2008-03-16 | Dow Corning Corporation | COMPOSITION OF CONTROLLED RELEASE. |
GB0312703D0 (en) | 2003-06-03 | 2003-07-09 | Oxonica Ltd | Agricultural compositions |
JP2005053728A (en) * | 2003-08-01 | 2005-03-03 | Dsl Japan Co Ltd | Amorphous silica particle having high oil absorption and high structural performance |
JP2005053744A (en) * | 2003-08-05 | 2005-03-03 | Dsl Japan Co Ltd | High oil absorptive amorphous silica particle |
TW200525015A (en) * | 2003-09-11 | 2005-08-01 | Taiyo Kagaku Kk | Porous silica having substance carried thereon |
EP1694307A2 (en) | 2003-10-21 | 2006-08-30 | PSIMEDICA Limited | Methods for the treatment of cancer |
GB0406819D0 (en) | 2004-03-26 | 2004-04-28 | Dow Corning | Controlled release compositions |
JP2005307120A (en) | 2004-04-26 | 2005-11-04 | Mitsubishi Chemicals Corp | Sustained release agent and sustained release material using the same |
GB0420016D0 (en) * | 2004-09-09 | 2004-10-13 | Leuven K U Res & Dev | Controlled release oral delivery system |
CN100352430C (en) * | 2005-03-09 | 2007-12-05 | 山东大学 | Self microemulsifying preparation of curcumin and its preparing process |
WO2006119779A2 (en) | 2005-05-10 | 2006-11-16 | Lifecycle Pharma A/S | A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution |
FR2894822B1 (en) | 2005-12-20 | 2011-11-18 | Pf Medicament | PHARMACEUTICAL COMPOSITION CONTAINING OMEGA-3 FATTY ACIDS |
US8920821B2 (en) | 2006-04-14 | 2014-12-30 | Perrigo Israel Pharmaceuticals Ltd. | Pharmaceutical compositions comprising silica microspheres |
AU2007247770B2 (en) | 2006-05-04 | 2013-07-18 | Reformpharm Pty Ltd | Drug release from nanoparticle-coated capsules |
US7691400B2 (en) | 2006-05-05 | 2010-04-06 | Medtronic Vascular, Inc. | Medical device having coating with zeolite drug reservoirs |
KR20080026754A (en) * | 2006-09-21 | 2008-03-26 | 주식회사 삼양사 | Release controlled particle comprising a biologically active substance, and preparing method thereof |
EP2150235A4 (en) | 2007-04-20 | 2013-07-03 | Univ South Australia | Nanoparticle-coated capsule formulation for dermal drug delivery |
US20100298447A1 (en) | 2007-11-02 | 2010-11-25 | Takeru Fujii | Composite product of low-solubility drug and surfactant, and process for production thereof |
EP2072042A1 (en) * | 2007-12-21 | 2009-06-24 | Lek Pharmaceuticals D.D. | Active pharmaceutical ingredient on solid support, amorphous and with improved solubility |
KR100950548B1 (en) * | 2008-01-10 | 2010-03-30 | 연세대학교 산학협력단 | A porous hollow silica nanoparticle, preparation method thereof, drug carrier and pharmacetical composition comprising the same |
DE102008000290A1 (en) | 2008-02-13 | 2009-08-20 | Evonik Degussa Gmbh | Storage stable product systems for premix formulations |
JP5437232B2 (en) | 2008-03-11 | 2014-03-12 | あすか製薬株式会社 | Solid dispersion, pharmaceutical composition thereof, and production method thereof |
US8188022B2 (en) | 2008-04-11 | 2012-05-29 | Amcol International Corporation | Multilayer fragrance encapsulation comprising kappa carrageenan |
US8778400B2 (en) | 2008-04-21 | 2014-07-15 | University Of South Australia | Nanoparticle-stabilized capsule formulation for treatment of inflammation |
AU2009282051A1 (en) | 2008-08-12 | 2010-02-18 | Castle Beach, L.L.C. | Active delivery system formulations |
GB0821928D0 (en) | 2008-12-01 | 2009-01-07 | Isis Innovation | Antibiotic nanomaterial |
DE102010003204A1 (en) * | 2010-03-24 | 2011-12-15 | Evonik Degussa Gmbh | Coarse particle carrier silicic acids |
KR20140003405A (en) | 2010-09-07 | 2014-01-09 | 오렉쏘 에이비 | A transdermal drug administration device |
US9980481B2 (en) | 2012-04-02 | 2018-05-29 | Basf Se | Granules obtainable by milling pesticide and silica, addition of adjuvant, and fluidized bed granulation |
-
2014
- 2014-01-30 ES ES14746507T patent/ES2908958T3/en active Active
- 2014-01-30 CN CN201480019478.7A patent/CN105102117A/en active Pending
- 2014-01-30 CN CN202010078625.5A patent/CN111389345A/en active Pending
- 2014-01-30 KR KR1020157023665A patent/KR102229036B1/en active IP Right Grant
- 2014-01-30 EP EP14746507.4A patent/EP2950923B1/en active Active
- 2014-01-30 JP JP2015556128A patent/JP6513031B2/en active Active
- 2014-01-30 WO PCT/US2014/013848 patent/WO2014120922A1/en active Application Filing
- 2014-01-30 US US14/764,363 patent/US10660856B2/en active Active
- 2014-01-30 PL PL14746507T patent/PL2950923T3/en unknown
-
2016
- 2016-05-25 HK HK16105942.0A patent/HK1217927A1/en unknown
-
2018
- 2018-10-18 JP JP2018197017A patent/JP6861679B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4157920A (en) | 1975-03-12 | 1979-06-12 | J. M. Huber Corporation | Novel precipitated siliceous products and methods for their use and production |
US4226743A (en) | 1979-03-12 | 1980-10-07 | W. R. Grace & Co. | Silica-alumina hydrogel catalyst |
US20030152771A1 (en) * | 1999-04-22 | 2003-08-14 | Preston Barry W. | Very high structure, highly absorptive hybrid silica and methods for making same |
US20120269792A1 (en) * | 2001-11-14 | 2012-10-25 | Jarrow Formulas, Inc. | Eutectic-based self-nanoemulsified drug delivery system |
US20050112232A1 (en) * | 2002-04-30 | 2005-05-26 | Jean-Marie Dollat | Animal feed supplement |
WO2004073689A1 (en) | 2003-02-19 | 2004-09-02 | Lifecycle Pharma A/S | Use of a silica or silica derivative as a sorption material |
US20090311159A1 (en) * | 2006-08-22 | 2009-12-17 | Evonik Degussa Gmbh | Fumed silica for use as auxiliary in pharmaceutical and cosmetic compositions |
WO2011144346A1 (en) * | 2010-05-21 | 2011-11-24 | Grace Gmbh & Co. Kg | Porous inorganic oxide particles and methods of making and using the same |
Non-Patent Citations (1)
Title |
---|
See also references of EP2950923A4 |
Also Published As
Publication number | Publication date |
---|---|
EP2950923B1 (en) | 2022-03-09 |
KR20150115860A (en) | 2015-10-14 |
CN105102117A (en) | 2015-11-25 |
JP2019048819A (en) | 2019-03-28 |
HK1217927A1 (en) | 2017-01-27 |
US10660856B2 (en) | 2020-05-26 |
EP2950923A4 (en) | 2016-10-19 |
JP2016508502A (en) | 2016-03-22 |
ES2908958T3 (en) | 2022-05-04 |
JP6513031B2 (en) | 2019-05-15 |
US20150366805A1 (en) | 2015-12-24 |
PL2950923T3 (en) | 2022-04-04 |
CN111389345A (en) | 2020-07-10 |
KR102229036B1 (en) | 2021-03-17 |
JP6861679B2 (en) | 2021-04-21 |
EP2950923A1 (en) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6861679B2 (en) | Porous silica gel as a carrier for liquid technology | |
Tan et al. | Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs | |
EP2919903B1 (en) | Compositions containing a biologically active material and a non-ordered inorganic oxide | |
JP2015521175A (en) | Cannabinoid-containing granule, process for producing the same, and oral dosage unit containing such granule | |
Choudhari et al. | Comparative evaluation of porous silica based carriers for lipids and liquid drug formulations | |
Midha et al. | Prospectives of solid self-microemulsifying systems in novel drug delivery | |
Shazly et al. | Dissolution improvement of solid self-emulsifying drug delivery systems of fenofibrate using an inorganic high surface adsorption material | |
CN108079308A (en) | Ubiquinone10With the nano structured lipid carrier and preparation method of n-octacosanol compounding | |
CN107921017A (en) | The method treated using cadotril composition | |
US11484501B2 (en) | Mechanochemical activated dry amorphisation by milling equilibrium between ap mesoporous silica | |
Singh et al. | Polymeric delivery systems for poorly soluble drugs | |
US20220354791A1 (en) | Mesoporous polymeric particulate material | |
Hasan et al. | Effect of Self-Microemulsifying Lipid Formulations on the Dissolution and Compaction Profiles of Tablets Containing Theophylline; A BCS Class I Compound | |
Nandal et al. | Novel Approaches of Self Emulsifying Drug Delivery Systems and Recent Patents: A Comprehensive Review | |
LETCHMANAN | ENHANCING BIO-PHARMACEUTICAL PROPERTIES OF POORLY SOLUBLE ANTI-MALARIAL DRUGS BY FORMULATING AMORPHOUS FORMS WITH BIOCOMPATIBLE EXCIPIENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480019478.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14746507 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014746507 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015556128 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20157023665 Country of ref document: KR Kind code of ref document: A |